CHIPS Program Seeks Feedback on Workforce Data

2026-06419 — Board of Overseers of the Malcolm Baldrige National Quality Award

The Board of Overseers for the Malcolm Baldrige National Quality Award is meeting virtually on June 11, 2026, to review and improve the Award program. This affects organizations aiming for top-quality performance in areas like business, education, and health. The meeting is open to the public and focuses on updates, ethics, and new ideas—no costs or deadlines for participants yet, but big improvements could be coming!

2026-06391 — Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; ASKCHIPS Information Collection

The National Institute of Standards and Technology (NIST) is asking for public feedback on their ASKCHIPS info collection form, which helps people easily request meetings or speakers from the CHIPS Program Office. This update aims to keep things smooth and simple for everyone involved, with comments due by June 1, 2026. If you’re involved in semiconductor incentives or just curious, this affects how you connect with the program—no big costs, just better communication!

2026-03586 — Visiting Committee on Advanced Technology

The National Institute of Standards and Technology’s Visiting Committee on Advanced Technology (VCAT) is holding a public virtual meeting on March 27, 2026, to review NIST’s policies, programs, and budget. This meeting affects U.S. industries and anyone interested in NIST’s work, with a chance to share comments by March 13. The committee will also prepare its 2025 annual report, helping shape future tech and innovation priorities.

2026-03303 — Eliminating Obsolete Regulations Related to the Advanced Technology Program and the Technology Innovation Program

NIST is cleaning house by removing old rules about two tech grant programs, the Advanced Technology Program and the Technology Innovation Program, which are no longer active or authorized by law. This update, effective February 19, 2026, helps keep things clear and current, so no one gets confused about these programs. No money or new programs are involved—just a tidy-up to keep the rulebook fresh!

2026-03307 — Eliminating Obsolete Marking Requirements for Toy, Look-Alike, and Imitation Firearms

Starting February 19, 2026, the old rules about marking toy and imitation guns from NIST are gone! Now, the Consumer Product Safety Commission (CPSC) is the boss of these rules, making things clearer and simpler for everyone. This change won’t cost businesses extra but will cut confusion and keep safety rules up to date.

2026-01256 — Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; NIST Invention Disclosure and Inventor Information Collection

NIST is updating its forms that inventors fill out when they create something new using NIST labs. This helps protect the U.S. government’s rights to these inventions and may start the patent process. If you’re an inventor or work with NIST, you might spend a little time filling out these forms, but it keeps everything official and fair!

Previous: 2026-05386 — Combined Notice of Filings

The Federal Energy Regulatory Commission got new filings about natural gas pipeline rates and refunds. Some companies want to cancel tariffs or change rates starting mid-March 2026, and folks have until late March or early April to share their thoughts. These changes could affect how much people pay or get refunded for natural gas services soon.

Next: 2026-05390 — General Considerations for the Use of New Approach Methodologies in Drug Development; Draft Guidance for Industry; Availability

The FDA just dropped a draft guide to help drug makers use new, smarter testing methods that can reduce animal testing and better predict human safety. This affects drug developers who want to submit safer, more reliable data for approval. Comments are open until May 18, 2026, so get involved early to shape the final rules and possibly save time and money in drug development.